Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers.
Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC).
These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Company Details
- Employees
- 56
- Founded
- -
- Address
- 11055 Flintkote Avenue, San Diego,california 92121,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- trovagene.com
- HQ
- San Diego, California
Cardiff Oncology Questions
Cardiff Oncology's website is trovagene.com
Cardiff Oncology's LinkedIn profile is https://www.linkedin.com/company/cardiffoncology
Cardiff Oncology has
56 employees.
View email and phone details for 56
employees at Cardiff Oncology.
Cardiff Oncology's industry is
Biotechnology Research
Cardiff Oncology's top competitors are
Bright Minds Biosciences,
Eton Pharmaceuticals,
Entera Bio Ltd.,
Kodiak Sciences,
Exicure,
Monopar Therapeutics Inc.,
Asp Isotopes,
Jasper Therapeutics,
Capricor Therapeutics, Inc.,
Rezolute, Inc..
Cardiff Oncology's categories are Biotechnology Research
Cardiff Oncology's founding year is 1999
